We serve Chemical Name:4-(2-aminoanilino)-4-oxobutanoic acid CAS:83549-10-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(2-aminoanilino)-4-oxobutanoic acid
CAS.NO:83549-10-4
Synonyms:F1202-0161;o-aminosuccinanilic acid
Molecular Formula:C10H12N2O3
Molecular Weight:208.21400
HS Code:2924299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:512.9ºC at 760 mmHg
Density:N/A
Index of Refraction:
PSA:92.42000
Exact Mass:208.08500
LogP:1.72630
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like F1202-0161 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,o-aminosuccinanilic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,F1202-0161 Use and application,o-aminosuccinanilic acid technical grade,usp/ep/jp grade.
Related News: When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. 4-(2-aminoanilino)-4-oxobutanoic acid manufacturer The continuous acceleration of the industrial transfer process has provided a huge market space for the fine chemical intermediate industry. 4-(2-aminoanilino)-4-oxobutanoic acid supplier The continuous acceleration of the industrial transfer process has provided a huge market space for the fine chemical intermediate industry. 4-(2-aminoanilino)-4-oxobutanoic acid vendor Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients. 4-(2-aminoanilino)-4-oxobutanoic acid factory When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. 4-(2-aminoanilino)-4-oxobutanoic acid manufacturer The continuous acceleration of the industrial transfer process has provided a huge market space for the fine chemical intermediate industry. 4-(2-aminoanilino)-4-oxobutanoic acid supplier The continuous acceleration of the industrial transfer process has provided a huge market space for the fine chemical intermediate industry. 4-(2-aminoanilino)-4-oxobutanoic acid vendor Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients. 4-(2-aminoanilino)-4-oxobutanoic acid factory When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau.
